# Pembrolizumab in Combination With CRT for LA-SCCHN

> **NCT02586207** · PHASE1 · COMPLETED · sponsor: **Sanford Health** · enrollment: 59 (actual)

## Conditions studied

- Head and Neck Cancer
- Squamous Cell Carcinoma
- Oral Cavity Cancer
- Oropharynx Cancer
- Hypopharynx Cancer
- Larynx Cancer
- Laryngeal Cancer

## Interventions

- **DRUG:** pembrolizumab (MK-3475)
- **DRUG:** Cisplatin
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT02586207
- **Lead sponsor:** Sanford Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2020-09-29
- **Final completion:** 2025-08
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2025-10-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586207, "Pembrolizumab in Combination With CRT for LA-SCCHN". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02586207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*